Dexfenfluramine
From Wikipedia, the free encyclopedia
| Image:Dexfenfluramine.png | |
|
Dexfenfluramine
|
|
| Systematic (IUPAC) name | |
| N-ethyl-1-[3-(trifluoromethyl)phenyl]-propan-2-amine | |
| Identifiers | |
| CAS number | 3239-44-9 |
| ATC code | A08AA04 |
| PubChem | 3337 |
| DrugBank | APRD00648 |
| Chemical data | |
| Formula | C12H16F3N |
| Mol. weight | 231.257 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 36% |
| Metabolism | ? |
| Half life | 17-20 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
- This article is about a drug branded as Redux. For the adjective meaning "being brought back", see Redux (word).
Dexfenfluramine, also marketed under the name Redux, is an anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the side-effects of the drug, such approval was withdrawn.
The drug was manufactured by Interneuron Pharmaceuticals and marketed by Wyeth-Ayerst Laboratories. It is the enantiomer of fenfluramine.
[edit] See also
[edit] References
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
